<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497471</url>
  </required_header>
  <id_info>
    <org_study_id>IronMal</org_study_id>
    <nct_id>NCT00497471</nct_id>
  </id_info>
  <brief_title>RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants</brief_title>
  <official_title>The Prevention of Anaemia and Malaria in Infants in an Area of Intense and Perennial Malaria Transmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agencia Española de Cooperación Internacional</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the efficacy of weekly iron supplementation and the
      efficacy of malaria chemoprophylaxis from 2 to 12 months of age in infants living in an area
      of intense and perennial malaria transmission
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      411 Tanzanian infants were randomly assigned to receive weekly malaria prophylaxis with
      Deltaprim™ (3.125 mg pyrimethamine plus 25 mg dapsone) or placebo from ages 2-12 months.
      Children were followed-up until age 4 years. Uncomplicated febrile malaria, severe malaria
      and anaemia morbidity were assessed through hospital-based passive surveillance.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Follow-up end in 1999
  </why_stopped>
  <start_date>February 1995</start_date>
  <completion_date type="Actual">July 1999</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Malaria</measure>
    <time_frame>During first year of life</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe Anemia (PCV &lt; 25%)</measure>
    <time_frame>During first year of life</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Malaria</measure>
    <time_frame>After first year of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Anemia (PCV &lt; 25%)</measure>
    <time_frame>After first year of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outpatient visits</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Admissions</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe malaria</measure>
  </secondary_outcome>
  <enrollment type="Actual">832</enrollment>
  <condition>Malaria</condition>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iron (2 mg/kg/daily)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Born in San Francis Designated District Hospital of Ifakara

        Exclusion Criteria:

          -  Obvious severe congenital malformation such as: spina bifida, hydrocephalus or
             anencepahlus

          -  Twins

          -  Birth weight &lt; 1,5 kg

          -  Clinical signs of cerebral asphyxia

          -  Clinical signs of neonatal or congenital infection

          -  Mother unreliable (deaf, mentally handicapped)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Day</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clara Menendez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for International Health, Hospital Clinic / Universitat Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ifakara Centre</name>
      <address>
        <city>Ifakara</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <results_reference>
    <citation>Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, Acosta CJ, Schellenberg DM, Galindo CM, Kimario J, Urassa H, Brabin B, Smith TA, Kitua AY, Tanner M, Alonso PL. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet. 1997 Sep 20;350(9081):844-50.</citation>
    <PMID>9310602</PMID>
  </results_reference>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2007</study_first_submitted>
  <study_first_submitted_qc>July 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2007</study_first_posted>
  <last_update_submitted>July 5, 2007</last_update_submitted>
  <last_update_submitted_qc>July 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2007</last_update_posted>
  <keyword>Plasmodium Falciparum</keyword>
  <keyword>Antimlarial chemoprophylaxis</keyword>
  <keyword>Iron supplementation</keyword>
  <keyword>Tanzania</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

